[제약사 리포트] 동아에스티, 1분기 만에 흑자 회복…자큐보 효과 톡톡

Dong-A ST has successfully returned to profitability by leveraging high-growth in-licensed drugs like Jacubo, reflecting a broader pharmaceutical trend of utilizing co-promotion to stabilize cash flow. However, the declining R&D investment ratio suggests a critical transition period where the company must balance short-term financial recovery with the long-term necessity of developing proprietary pipelines.